Automated Expansion of Primary Human T Cells in Scalable and Cell‐Friendly Hydrogel Microtubes for Adoptive Immunotherapy
暂无分享,去创建一个
Ou Wang | Yuguo Lei | Jack Rauch | Haishuang Lin | H. Viljoen | Y. Lei | Qiang Li | Braden Harm | Hendrik J Viljoen | Chi Zhang | Erika Van Wyk | Haishuang Lin | Qiang Li | O. Wang | Chi Zhang | J. Rauch | Erika Van Wyk | Braden Harm
[1] R. Orentas,et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy , 2015, Cancer Gene Therapy.
[2] Vladimir Mironov,et al. Tissue spheroid fusion‐based in vitro screening assays for analysis of tissue maturation , 2010, Journal of tissue engineering and regenerative medicine.
[3] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[4] S. Rosenberg,et al. Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.
[5] Stefan Miltenyi,et al. Integrated Clinical Scale Manufacturing System for Cellular Products Derived by Magnetic Cell Separation, Centrifugation and Cell Culture , 2013 .
[6] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[7] M. Sabatino,et al. Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates , 2016, Transfusion.
[8] P. Itsykson,et al. Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension , 2010, Nature Biotechnology.
[9] S. Rosenberg,et al. Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor , 2012, Journal of Translational Medicine.
[10] I. Pastan,et al. Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers , 2010, Clinical Cancer Research.
[11] M. Dudley,et al. Bioreactors get personal , 2012, Oncoimmunology.
[12] G. Kvalheim,et al. Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. , 2010, Journal of immunological methods.
[13] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[14] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Praveen Shukla,et al. Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. , 2015, Stem cell research.
[16] X. Wang,et al. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies , 2015, Cancer Gene Therapy.
[17] R. McKay,et al. Developmental insights from early mammalian embryos and core signaling pathways that influence human pluripotent cell growth and differentiation. , 2014, Stem cell research.
[18] Andreas Fouras,et al. Flow Characterization of a Spinner Flask for Induced Pluripotent Stem Cell Culture Application , 2014, PloS one.
[19] S. Riddell,et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. , 2011, Blood.
[20] Daniel Li,et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.
[21] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[22] K. Peggs,et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. , 2016, Cytotherapy.
[23] Todd C McDevitt,et al. The multiparametric effects of hydrodynamic environments on stem cell culture. , 2011, Tissue engineering. Part B, Reviews.
[24] S. Rosenberg,et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[25] B. Levine,et al. Adoptive immunotherapy for cancer or viruses. , 2014, Annual review of immunology.
[26] A. Cerwenka,et al. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy , 2015, Cytotherapy.
[27] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[28] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Melissa A. Kinney,et al. Hydrodynamic modulation of pluripotent stem cells , 2012, Stem Cell Research & Therapy.
[30] R. McKay,et al. Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics. , 2014, Cell stem cell.
[31] David V. Schaffer,et al. A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation , 2013, Proceedings of the National Academy of Sciences.
[32] S. Rosenberg,et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.
[33] Marianna Sabatino,et al. Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment , 2012, Journal of immunotherapy.
[34] Yuguo Lei,et al. Developing Defined and Scalable 3D Culture Systems for Culturing Human Pluripotent Stem Cells at High Densities , 2014, Cellular and molecular bioengineering.
[35] W. Wilson,et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.
[36] Catarina Brito,et al. Process engineering of human pluripotent stem cells for clinical application. , 2012, Trends in biotechnology.
[37] Y. Lei,et al. Scalable Production of Glioblastoma Tumor-initiating Cells in 3 Dimension Thermoreversible Hydrogels , 2016, Scientific Reports.
[38] Y. Lei,et al. An Integrated Miniature Bioprocessing for Personalized Human Induced Pluripotent Stem Cell Expansion and Differentiation into Neural Stem Cells , 2017, Scientific Reports.
[39] C. Gahmberg,et al. LFA-1 integrin antibodies inhibit leukocyte α4β1-mediated adhesion by intracellular signaling. , 2016, Blood.
[40] Seth M Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[41] D. Porter,et al. Chimeric antigen receptor T cell therapy: 25years in the making. , 2016, Blood reviews.
[42] D. Mooney,et al. Alginate: properties and biomedical applications. , 2012, Progress in polymer science.
[43] Michel Sadelain,et al. Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy , 2009, Journal of immunotherapy.
[44] S. Rosenberg,et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[46] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[47] Suzanne S Farid,et al. Human pluripotent stem cell-derived products: Advances towards robust, scalable and cost-effective manufacturing strategies , 2014, Biotechnology journal.
[48] G. Schuler,et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer , 2009, Gene Therapy.
[49] S. Katz,et al. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases , 2015, Clinical Cancer Research.
[50] Robert Zweigerdt,et al. Controlling Expansion and Cardiomyogenic Differentiation of Human Pluripotent Stem Cells in Scalable Suspension Culture , 2014, Stem cell reports.
[51] Wee Keat Chong,et al. Time-resolved video analysis and management system for monitoring cardiomyocyte differentiation processes and toxicology assays. , 2014, Biotechnology journal.
[52] B. Levine. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells , 2015, Cancer Gene Therapy.
[53] David Hsu,et al. Optimizing the production of suspension cells using the G-Rex “M” series , 2014, Molecular therapy. Methods & clinical development.
[54] H. Abken,et al. Cancer gene therapy with T cell receptors and chimeric antigen receptors. , 2015, Current opinion in pharmacology.
[55] Anthony Walker,et al. Commercialization of cellular immunotherapies for cancer. , 2016, Biochemical Society transactions.
[56] S. Jagannath,et al. BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity , 2012 .